XORTX Therapeutics Inc. (XRTX) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] XORTX Therapeutics Inc (XRTX.V) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, XORTX is a tiny late-stage biotech trying to develop treatments for gout and progressive kidney disease, but right now it looks much more like a clinical-stage funding story than an operating business. > **📍 Basic Profile** > > Market Cap **$3.57 million** · Pharmaceuticals · TSX VENTURE EXCHANGE - NEX · Price **$0.43** > **⚡ 3 Things You Should Know** > > 1. 💸 Not a real earnings business yet: Profitability is deeply negative, with **ROE at -120.33%** and **net margin at -260%** if the reported figure is read as percentage-style loss-making economics—basically, this is still a biotech burning capital rather than monetizing a product. > > 2. ⚠️ Reverse split is a red flag on market positioning: The company recently announced a **1-for-5 share consolidation**, which usually means management is trying to shore up listing optics and share-price perception; in other words, capital markets pressure matters here. > > 3. 🧪 Valuation looks “cheap” only on paper: With **P/S at 0.003x** and the stock trading near its **52-week low**, it may screen as dirt cheap, but that’s not the same as being undervalued—what really matters is whether the pipeline can create future commercial value before cash runs thin. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin **-260%** (reported TTM figure suggests deep losses), ROE **-120.33%** | > | Growth Rate | Slow🐢 | 3-year revenue growth **-20.19%** | > | Financial Health | Moderate💛 | Debt-to-equity **1.79%** is low, current ratio **2.11** is decent | > | Valuation | Hard to judge / Speculative | PE **[Data unavailable]**, PB **1.90x**, P/S **0.003x** | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** XORTX is developing pharmaceutical therapies for gout and kidney disease, aiming to make money in the future through drug commercialization or partnership/licensing, but current operating revenue appears minimal. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Drug development / pipeline programs | [Data unavailable] | [Data unavailable] | This is the economic engine investors are really betting on | | Current reported revenue | [Data unavailable] | ↓ | P/S near zero and negative multi-year revenue growth suggest very limited current sales | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 21.01% | Below Average | Suggests limited pricing power or non-scaled economics; not unusual for a pre-commercial biotech | | Net Margin | -260%* | Below Average | The company is losing far more than it earns; operating model is not self-funding | | ROE | -120.33% | Below Average | Shareholder capital is being consumed quickly rather than compounding | \*Based on provided TTM metric format; reported value likely reflects deeply negative profitability. --- #### 📈 How's the Growth? **Growth Assessment:** Slowing / Stagnant | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable for latest year] | [Data unavailable] | 3-year trend negative | | Profit Growth | [Data unavailable] | [Data unavailable] | Still deeply loss-making | **Growth Quality:** > What’s worth noting is that this doesn’t look like a company with healthy operating growth yet. The reported **3-year revenue growth of -20.19%** suggests the current business base is shrinking or too small to matter, so the real “growth” story depends on clinical progress, regulatory milestones, or partnership deals—not on existing commercial traction. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a startup with very little debt and okay short-term liquidity, but no stable paycheck—so survival depends more on funding access than on business cash generation. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 1.79% debt-to-equity | <60% safe | ✅Safe | | Current Ratio | 2.11 | >1.5 healthy | ✅Safe | | Cash Flow | Cash flow per share **-4.98** | >0 | 🚨Negative | What you might care about is this: low debt is good, but for a micro-cap biotech, **negative cash flow matters more than low leverage**. If there’s no meaningful revenue base, future dilution can become the default financing tool. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: **$0.485** - 52-Week High: **$1.97** - Current: **$0.43**, **below the stated 52-week low in the provided data** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(Below 0% position based on provided range) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE **[Data unavailable]** | 5-year avg **[Data unavailable]** | [Data unavailable] | | vs Peers | PE **[Data unavailable]** | Industry avg **[Data unavailable]** | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the market is not paying for current earnings at all. At this price, investors are mainly betting that XORTX can: **(1)** keep funding operations, **(2)** advance its pipeline without major setbacks, and **(3)** eventually create a licensing, partnership, or approval event that re-rates the stock. Without that, “cheap” can stay cheap for a long time. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-03-31 / 2026-04-01* | Announced **1-for-5 share consolidation**, effective April 6, 2026 | Negative / Mixed — usually a sign of capital-markets pressure, though it may help listing compliance optics | | 2026-03-25* | Delayed the 1-for-5 share consolidation pending approvals | Neutral / Slightly Negative — shows process friction and added uncertainty | | 2026-03-05* | Filed and mailed annual and special meeting documents | Neutral — standard governance step, but may tie into capital structure decisions | \*Dates converted approximately from provided timestamps/news flow. --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 21.01% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -260%* | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -120.33% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↓ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | \*Based on provided metric formatting and interpreted as deeply negative margin. --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2024-03-31 | -$0.26 | -$1.24 | -372.20% Miss 😟 | | 2023-06-30 | -$2.27 | -$1.09 | +52.08% Beat 😀 | | 2023-03-31 | -$2.09 | -$0.99 | +52.65% Beat 😀 | | 2022-12-31 | -$2.45 | -$1.80 | +26.66% Beat 😀 | **Earnings Trend Interpretation:** What’s interesting is that the company had several quarters of “beats,” but in biotech that can be misleading because beating a very negative estimate doesn’t mean the business is healthy. The most recent quarter was a **huge miss**, which tells you analyst visibility is weak and results can swing sharply—typical of high-risk development-stage names. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 4 firms | 80% | | Hold | 1 firm | 20% | | Sell | 0 firms | 0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median **[Data unavailable]**) **vs Current Price:** [Data unavailable] **Insider Activity:** Net **[Data unavailable]** in past 3 months > No insider transaction data was provided. In general, insider buying can signal management confidence, while heavy selling in a stressed micro-cap can raise questions—but here we can’t draw a conclusion. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Financing/Dilution Risk:** Negative cash flow and weak profitability mean the company may need to raise more capital → If this happens, it could lead to shareholder dilution. 2. **Execution Risk:** This is a pipeline-dependent biotech with limited operating revenue → If trial, regulatory, or partnership progress stalls, the stock could lose support quickly. 3. **Market Structure Risk:** The recent reverse split/share consolidation suggests pressure around share-price optics and market access → If sentiment worsens, liquidity and volatility could become bigger problems. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** XORTX is a very small, speculative biotech whose value depends far more on future drug development success than on current business performance. > > **Key strength:** The balance sheet doesn’t look debt-heavy, and short-term liquidity is not the immediate problem. > > **Key risk:** The big issue is that it’s still losing money heavily, generating negative cash flow, and now dealing with reverse-split dynamics—so funding risk is front and center. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis